BioCryst Pharmaceuticals Inc (BCRX)

NASDAQ
14.33
+0.08(+0.56%)
Pre Market
13.95
-0.38(-2.65%)
- Real-time Data
  • Volume:
    2,107,260
  • Day's Range:
    14.10 - 14.39
  • 52 wk Range:
    7.61 - 19.99

BCRX Overview

Prev. Close
14.25
Day's Range
14.1-14.39
Revenue
203.61M
Open
14.34
52 wk Range
7.61-19.99
EPS
-1.15
Volume
2,107,260
Market Cap
2.66B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
3,070,085
P/E Ratio
-12.47
Beta
2.2
1-Year Change
-1.65%
Shares Outstanding
185,945,016
Next Earnings Date
Nov 08, 2022
What is your sentiment on BioCryst?
or
Market is currently closed. Voting is open during market hours.

BioCryst Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

BioCryst Pharmaceuticals Inc Analysis

BioCryst Pharmaceuticals Inc Company Profile

BioCryst Pharmaceuticals Inc Company Profile

Employees
358

BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralNeutralBuyBuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong BuyNeutral
SummaryBuyBuyNeutralStrong BuyBuy
  • This hammering looks a little too severe.
    0
    • what's wrong?
      1
      • Clinical trial product halt.
        0
    • Man...
      1
      • what a joke with earnings worse in years and with FDA approval seriously
        0
        • The Food and Drug Administration (FDA) approved BioCryst's first drug, Orladeyo, a little over a year ago. The first few quarters post-launch for the drug, which prevents attacks of hereditary angioedema, were less than inspiring. But preliminary fourth-quarter figures released today suggest the drug really can achieve more than $1 billion in annual sales.
          3
          • Why up so much?
            0
            • preliminary earnings is looking super good 👌
              0
          • premaket down 6,90 %, any news?'
            0
            • Earnings were bad?
              1
              • not really
                0
            • Buy
              0
              • Buy
                0